Yutaro Sasaki

Yutaro Sasaki

Auto-generated profile, based on publicly available information

Yutaro Sasaki

Department of Nutrition, Graduate School of Human Life and Ecology, Osaka Metropolitan University, Osaka 538-8525, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
YYYuri Yasuda
Yuri Yasuda
TTTamaki Tokumatsu
Tamaki Tokumatsu
CUChiharu Ueda
Chiharu Ueda
MSManami Sakai
Manami Sakai
YSYutaro Sasaki
Yutaro Sasaki
Akiko Kojima-YuasaAkiko Kojima-Yuasa
Akiko Kojima-Yuasa
Parkinson’s disease (PD) is a degenerative neurological disorder defined by the deterioration and loss of dopamine-producing neurons in the substantia nigra, leading to a range of motor impairments and non-motor symptoms. The underlying mechanism of this neurodegeneration remains unclear. This research examined the neuroprotective properties of Ecklonia cava polyphenols (ECPs) in mitigating neuronal damage induced by rotenone via the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)–antioxidant response element (ARE) pathway. Using human neuroblastoma SH-SY5Y cells and PD model mice, we found that ECP, rich in the antioxidant polyphenol phlorotannin, boosted the gene expression and functionality of the antioxidant enzyme NAD(P)H quinone oxidoreductase-1. ECP also promoted Nrf2 nuclear translocation and increased p62 expression, suggesting that p62 helps sustain Nrf2 activation via a positive feedback loop. The neuroprotective effect of ECP was significantly reduced by Compound C (CC), an AMP-activated protein kinase (AMPK) inhibitor, which also suppressed Nrf2 nuclear translocation. In PD model mice, ECPs improved motor functions impaired by rotenone, as assessed by the pole test and wire-hanging test, and restored intestinal motor function and colon tissue morphology. Additionally, ECPs increased tyrosine hydroxylase expression in the substantia nigra, indicating a protective effect on dopaminergic neurons. These findings suggest that ECP has a preventative effect on PD.

1 January 2022 in Nutrition Research and Practice
Verified
Journal Article
Open access
PDF file
YSYutaro Sasaki
Yutaro Sasaki
Akiko Kojima-YuasaAkiko Kojima-Yuasa
Akiko Kojima-Yuasa
HTHinako Tadano
Hinako Tadano
AMAyaka Mizuno
Ayaka Mizuno
AKAtsushi Kon
Atsushi Kon
TNTOSHIO NORIKURA
TOSHIO NORIKURA
Sasaki Y, et al. Nutr Res Pract. 2022 Apr;16(2):147-160. https://doi.org/10.4162/nrp.2022.16.2.147

15 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
SNSaki Nakamatsu
Saki Nakamatsu
MNMiki Nakata
Miki Nakata
TNTOSHIO NORIKURA
TOSHIO NORIKURA
YSYutaro Sasaki
Yutaro Sasaki
IMIsao Matsui-Yuasa
Isao Matsui-Yuasa
Akiko Kojima-YuasaAkiko Kojima-Yuasa
Akiko Kojima-Yuasa
Background: As a key contributor to metabolic disorders, obesity is recognized as a critical global health challenge. Adipocyte differentiation depends on the mitotic clonal expansion (MCE) phase, which is controlled by oxidative balance and transcription factors like C/EBPβ. Sesaminol, a lignan derived from Sesamum indicum, has potent antioxidant properties. This study aimed to investigate whether sesaminol suppresses adipogenesis by modulating ROS signaling, MCE, and the Nrf2-ARE pathway. Methods: In the early period of adipogenic induction, 3T3-L1 preadipocytes received treatment with sesaminol. Adipogenic development was evaluated through Oil Red O staining together with the assay of GPDH activity. Assays of cell proliferation and expression of cell cycle-related proteins, along with ROS measurement, qRT-PCR, Western blotting, and immunofluorescence, were performed to evaluate the effects on oxidative stress, transcriptional regulation, and AMPK-Nrf2 signaling. Results: Sesaminol significantly inhibited lipid accumulation and GPDH activity without cytotoxicity. It suppressed MCE by inhibiting DNA synthesis and reducing the expression of cyclin E1/E2 and CDK2. Sesaminol decreased C/EBPβ expression and its nuclear localization, resulting in lower levels of C/EBPα and PPARγ. It also reduced intracellular ROS, promoted nuclear translocation of Nrf2, and upregulated antioxidant genes HO-1 and GCLC. AMPK phosphorylation was concurrently enhanced. Conclusions: Sesaminol inhibits early adipogenesis by suppressing ROS-mediated MCE and activating the AMPK-Nrf2-ARE signaling pathway, leading to downregulation of key adipogenic transcription factors. The present study supports the potential of sesaminol as an effective strategy for obesity prevention.

9 May 2025 in Molecules
Verified
Journal Article
Open access
PDF file
YOYuji Onuki
Yuji Onuki
NNNaoki Nanashima
Naoki Nanashima
YSYutaro Sasaki
Yutaro Sasaki
Akiko Kojima-YuasaAkiko Kojima-Yuasa
Akiko Kojima-Yuasa
TNTOSHIO NORIKURA
TOSHIO NORIKURA
Malnutrition and aging are major factors that inhibit myoblast differentiation, leading to a decline in muscle function and contributing to sarcopenia development. This study aimed to elucidate the role of nutrients in myoblast differentiation by establishing a culture system at physiological glucose levels and investigating the effects of ketone bodies and oxaloacetate. We successfully cultured myoblasts at physiological glucose concentrations in a hydrophobic membrane filter-equipped culture flask. Under these conditions, ketone bodies and oxaloacetate synergistically upregulated myogenic differentiation markers (Lmod2 and Ckm), indicating enhanced differentiation. Additionally, oxaloacetate upregulated mitochondrial biogenesis markers (mitochondrial DNA copy number and Cs), whereas ketone bodies promoted Akt phosphorylation, a key regulator of differentiation, via the PI3K/Akt/mTOR pathway. These results suggest that the intake of ketone bodies and oxaloacetate effectively prevents sarcopenia by synergistically promoting myoblast differentiation via distinct molecular mechanisms, suggesting a potential new nutritional strategy.